The surgeon's role in breast cancer chemoprevention

Breast Disease

Volumn 12, Issue , 2001, Pages 103-112

  Brinkmann, E ^a   Morrow, M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ACCURACY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER RISK; CARCINOMA IN SITU; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SYNTHESIS; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; INVASIVE CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; MULTICENTER STUDY; NONHUMAN; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RAT; RISK FACTOR; SURGEON; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0034846858     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2001-12111     Document Type: Article

References (48)

1. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy
2. Prophylactic mastectomy and inherited predisposition to breast carcinoma
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
4. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
5. Validation of a breast cancer risk assessment model in women with a positive family history
6. Validation of the Gail et al. model for predicting individual breast cancer risk
7. Validation studies for models projecting the risk of invasive and total breast cancer incidence
8. Predictors of satisfaction with bilateral prophylactic mastectomy
9. Contralateral breast cancer: Annual incidence and risk paramenters
10. Contralateral breast cancer: Clinical characteristics and impact on prognosis
11. Risk of contralateral breast cancer in Denmark 1943-1980
12. Lobular neoplasia. Long term risk of breast cancer and relation to other factors
13. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years
14. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study
15. Frequency of breast cancer attributable to BRCA-1 in a population based series of Amercinan women
16. Breast and ovarian cancer incidence in BRCA-1 mutation carriers
17. The risk of cancer associated with specific mutations of BRCA-1 and BRCA-2 among Ashkenazi Jews
18. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer
19. Hormonal pathogenesis of adenocarcinoma of the breast
20. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the demethylbenzanthracene (DMBA)-induced rat mammary carcinoma model
21. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
22. Pharmacology of tamoxifen in laboratory animals
23. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy
24. Tamoxifen and contralateral breast cancer
25. Tamoxifen for early breast cancer: An overview of the randomized trials
26. Development of antiestrogens and their use in breast cancer
27. Long-term adjuvant tomoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women
28. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
29. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
30. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
31. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment
32. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer
33. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholestenol conversion to lathosterol in women with breast cancer
34. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
35. Interim analysis of the incidence of breast cancer in the Royal Marsden hospital tamoxifen randomized chemoprevention trial
36. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women
37. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
38. Tamoxifen therapy for breast cancer and endometrial cancer risk
39. Health-related quality of life and tamoxifen in breast cancer prevention
40. Tamoxifen, raloxifene and the prevention of breast cancer
41. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
42. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylivea induced rat mammary carcinoma model
43. Effects of a new antiestrogen keoxifene (LY156758) on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
44. Effects of raloxifene on bone-mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women
45. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
46. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
47. Raloxifene reduces incident primary breast cancers. Integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women